Neal Shore, MD, FACS

Rana R. McKay, MD, FASCO, and Neal D. Shore, MD, FACS, explain ARASEC's use of a synthetic historical control arm derived from the CHAARTED trial, a design approach they describe as both ethically necessary and methodologically efficient.

This episode examines how indirect trial comparisons can help guide ARPI selection in metastatic castration-sensitive prostate cancer when head-to-head studies are unavailable, while emphasizing the importance of patient-specific factors, tolerability, and clinical judgment.

In this video, Neal D. Shore, MD, FACS, and Rana R. McKay, MD, FASCO, discuss the evolving treatment landscape for metastatic hormone-sensitive prostate cancer and the clinical rationale for evaluating darolutamide (Nubeqa) plus ADT in a US patient population.

PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics.

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA.

This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.

Real-world PSMA PET in prostate cancer reveals reporting variability, limits at low PSA, and mixed FDG PET value—what clinicians learn in practice.

PSMA PET interpretation standards evolve, with SUV reporting and staging differences across settings shaping therapy choices, sequencing, and metastasis-directed radiation decisions.

PSMA PET scans reshape prostate cancer care—learn who should interpret results, how reports vary, and why a team approach guides treatment.

Learn how emerging advanced scans outpace CT and bone scans in finding micrometastatic prostate cancer and shaping treatment teamwork.

An expert discusses how KEYNOTE-905 sets the stage for the next generation of bladder cancer research and multidisciplinary care, shaping the evolving future of MIBC treatment.

An expert discusses strategies for optimizing perioperative immunotherapy use, managing toxicity, and ensuring adherence as KEYNOTE-905 transitions from trial evidence to clinical practice.

An expert discusses how KEYNOTE-905 establishes a new evidence-based systemic therapy option that transforms the management and prognosis of patients with muscle-invasive bladder cancer.

An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with high-risk T2N0 disease.

An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, significantly improving survival outcomes and redefining curative treatment strategies.

Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress.

Explore the complexities of treatment options for metastatic hormone-sensitive prostate cancer, emphasizing shared decision-making and patient considerations.

Research explores the effectiveness of Aerote in treating metastatic hormone-sensitive prostate cancer, focusing on patient subgroups and genetic factors.

Explore the potential of ultra-low PSA testing in managing metastatic hormone-sensitive prostate cancer, balancing accessibility and cost considerations.

Explore the latest advancements in clinical trials for metastatic hormone-sensitive prostate cancer, focusing on innovative treatments and testing methods.

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.

Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.

A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, and LATITUDE while highlighting the nuanced differences in adverse effect profiles and tolerability among these agents.

A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of the study design and topline results.

Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC.

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

Panelists examine disease heterogeneity in NMIBC and discuss a balanced treatment approach that prioritizes patient quality of life and surgery effectiveness.